{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:02:31Z","timestamp":1740142951020,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Advanced therapy-refractory parotid gland carcinomas have a\u00a0poor prognosis with limited therapy options. We used molecular profiling to offer molecular guided therapies to patients with advanced metastatic parotid gland malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective analysis we describe the molecular profiling of ten patients diagnosed with therapy-refractory metastatic parotid gland malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified seven genetic aberrations in five patients: two mutations in CDKN2A and one mutation in APC, ATM, TP53, SMARCB1 and FGFR1, respectively. No mutations were detected in five patients. The IHC demonstrated frequent expressions of EGFR and p\u2011mTOR, as well as PTEN in eight patients. For four fifths (<jats:italic>n<\/jats:italic>\u202f=\u20098) of the patients, a\u00a0targeted therapy was suggested. Eventually, three patients received the targeted therapy recommendation and one patient achieved stable disease for 14\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A total of eight therapy recommendations were provided. Based on our observations, molecular-guided therapies may be a\u00a0feasible treatment approach for this rare disease entity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-020-01778-8","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T15:07:30Z","timestamp":1607526450000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecularly guided treatment of metastatic parotid gland carcinoma in adults"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6498","authenticated-orcid":false,"given":"Hossein","family":"Taghizadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"F\u00fcreder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"1778_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000358776","volume":"24","author":"KV Holmberg","year":"2014","unstructured":"Holmberg\u00a0KV, Hoffman\u00a0MP. Anatomy, biogenesis and regeneration of salivary glands. Monogr Oral Sci. 2014;24:1\u201313.","journal-title":"Monogr Oral Sci"},{"key":"1778_CR2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1267\/ahc.12013","volume":"45","author":"O Amano","year":"2012","unstructured":"Amano\u00a0O, Mizobe\u00a0K, Bando\u00a0Y, Sakiyama\u00a0K. Anatomy and histology of rodent and human major salivary glands: -overview of the Japan salivary gland society-sponsored workshop. Acta Histochem Cytochem. 2012;45:241\u201350.","journal-title":"Acta Histochem Cytochem"},{"key":"1778_CR3","volume-title":"Anatomy, head and neck, parotid gland","author":"HM Chason","year":"2018","unstructured":"Chason\u00a0HM, Downs\u00a0BW. Anatomy, head and neck, parotid gland. Treasure Island: StatPearls; 2018."},{"key":"1778_CR4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","volume":"11","author":"RR Seethala","year":"2017","unstructured":"Seethala\u00a0RR, Stenman\u00a0G. Update from the 4th edition of the world health organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11:55\u201367.","journal-title":"Head Neck Pathol"},{"key":"1778_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1758-3284-3-40","volume":"3","author":"K Ho","year":"2011","unstructured":"Ho\u00a0K, Lin\u00a0H, Ann\u00a0DK, Chu\u00a0PG, Yen\u00a0Y. An overview of the rare parotid gland cancer. Head Neck Oncol. 2011;3:40.","journal-title":"Head Neck Oncol"},{"issue":"4","key":"1778_CR6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/00016480500401035","volume":"126","author":"I Schwentner","year":"2006","unstructured":"Schwentner\u00a0I, Obrist\u00a0P, Thumfart\u00a0W, Sprinzl\u00a0G. Distant metastasis of parotid gland tumors. Acta Otolaryngol. 2006;126(4):340\u20135.","journal-title":"Acta Otolaryngol"},{"key":"1778_CR7","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1017\/S0022215116000566","volume":"130","author":"S Sood","year":"2016","unstructured":"Sood\u00a0S, McGurk\u00a0M, Vaz\u00a0F. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J\u00a0Laryngol Otol. 2016;130:S142\u2013S9.","journal-title":"J Laryngol Otol"},{"key":"1778_CR8","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.18632\/oncotarget.13952","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang\u00a0X, Luo\u00a0Y, Li\u00a0M, Yan\u00a0H, Sun\u00a0M, Fan\u00a0T. Management of salivary gland carcinomas\u2014a\u00a0review. Oncotarget. 2017;8:3946\u201356.","journal-title":"Oncotarget"},{"issue":"3","key":"1778_CR9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hed.21706","volume":"34","author":"V Vander Poorten","year":"2012","unstructured":"Vander Poorten\u00a0V, Bradley\u00a0PJ, Takes\u00a0RP, Rinaldo\u00a0A, Woolgar\u00a0JA, Ferlito\u00a0A. Diagnosis and management of parotid carcinoma with a\u00a0special focus on recent advances in molecular biology. Head Neck. 2012;34(3):429\u201340.","journal-title":"Head Neck"},{"key":"1778_CR10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0002-9610(78)90262-3","volume":"136","author":"RH Spiro","year":"1978","unstructured":"Spiro\u00a0RH, Huvos\u00a0AG, Berk\u00a0R, Strong\u00a0EW. Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367\u00a0cases. Am J Surg. 1978;136:461\u20138.","journal-title":"Am J Surg"},{"key":"1778_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjoto.2004.06.017","volume":"26","author":"N Bhattacharyya","year":"2005","unstructured":"Bhattacharyya\u00a0N, Fried\u00a0MP. Determinants of survival in parotid gland carcinoma: a\u00a0population-based study. Am J Otolaryngol. 2005;26:39\u201344.","journal-title":"Am J Otolaryngol"},{"key":"1778_CR12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild\u00a0A, Grob\u00a0JJ, Demidov\u00a0LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a\u00a0multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358\u201365.","journal-title":"Lancet"},{"issue":"9742","key":"1778_CR13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang\u00a0YJ, Van Cutsem\u00a0E, Feyereislova\u00a0A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a\u00a0phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"key":"1778_CR14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian\u00a0H, Sawyers\u00a0C, Hochhaus\u00a0A, et\u00a0al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N\u00a0Engl J Med. 2002;346:645\u201352.","journal-title":"N Engl J Med"},{"key":"1778_CR15","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff\u00a0DD, Stephenson\u00a0JJ Jr., Rosen\u00a0P, et\u00a0al. Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers. J\u00a0Clin Oncol. 2010;28:4877\u201383.","journal-title":"J Clin Oncol"},{"key":"1778_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00391-2017","author":"IR Konig","year":"2017","unstructured":"Konig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017 Oct 19;50(4):1700391. https:\/\/doi.org\/10.1183\/13993003.00391-2017.","journal-title":"Eur Respir J"},{"key":"1778_CR17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archsurg.1990.01410130113018","volume":"125","author":"DC Allred","year":"1990","unstructured":"Allred DC, Bustamante MA, Daniel CO. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107\u201313.","journal-title":"Arch Surg"},{"key":"1778_CR18","first-page":"205","volume":"59","author":"D Sygut","year":"2008","unstructured":"Sygut\u00a0D, Bien\u00a0S, Ziolkowska\u00a0M, Sporny\u00a0S. Immunohistochemical expression of androgen receptor in salivary gland cancers. Pol J Pathol. 2008;59:205\u201310.","journal-title":"Pol J Pathol"},{"issue":"2","key":"1778_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers9020017","volume":"9","author":"MG Dalin","year":"2017","unstructured":"Dalin MG, Watson PA, Ho AL, Morris LG. Androgen Receptor Signaling in Salivary Gland Cancer. Cancers (Basel). 2017;9(2):17. https:\/\/doi.org\/10.3390\/cancers9020017.","journal-title":"Cancers (Basel)"},{"key":"1778_CR20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/RVTP1G0Q727WJUQD","volume":"119","author":"SM Nasser","year":"2003","unstructured":"Nasser\u00a0SM, Faquin\u00a0WC, Dayal\u00a0Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a\u00a0subset of malignant salivary gland tumors. Am J Clin Pathol. 2003;119:801\u20136.","journal-title":"Am J Clin Pathol"},{"key":"1778_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0973-029X.140732","volume":"18","author":"J Salehinejad","year":"2014","unstructured":"Salehinejad\u00a0J, Mohtasham\u00a0N, Bagherpour\u00a0A, Abbaszadeh-Bidokhty\u00a0H, Ghazi\u00a0A. Evaluation of c\u2011kit protein (CD117) expression in common salivary gland neoplasms. J\u00a0Oral Maxillofac Pathol. 2014;18:177\u201382.","journal-title":"J Oral Maxillofac Pathol"},{"key":"1778_CR22","first-page":"1376","volume":"33","author":"H Tariq","year":"2017","unstructured":"Tariq\u00a0H, Anjum\u00a0S, Din\u00a0HU, Akhtar\u00a0F. Diagnostic utility of C\u2011kit protein (CD117) expression in differentiating adenoid cystic carcinoma and polymorphous low grade Adenocarcinoma. Pak J Med Sci. 2017;33:1376\u201380.","journal-title":"Pak J Med Sci"},{"key":"1778_CR23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/01.MP.0000018973.17736.F8","volume":"15","author":"CR Penner","year":"2002","unstructured":"Penner\u00a0CR, Folpe\u00a0AL, Budnick\u00a0SD. C\u2011kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol. 2002;15:687\u201391.","journal-title":"Mod Pathol"},{"key":"1778_CR24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0714.2006.00421.x","volume":"35","author":"KB Sorensen","year":"2006","unstructured":"Sorensen\u00a0KB, Godballe\u00a0C, de Stricker\u00a0K, Krogdahl\u00a0A. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J\u00a0Oral Pathol Med. 2006;35:286\u201391.","journal-title":"J Oral Pathol Med"},{"key":"1778_CR25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00718645","volume":"415","author":"K Yamada","year":"1989","unstructured":"Yamada\u00a0K, Iwai\u00a0K, Okada\u00a0Y, Mori\u00a0M. Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol. 1989;415:523\u201331.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"1778_CR26","first-page":"435","volume":"19","author":"J Shang","year":"2008","unstructured":"Shang\u00a0J, Shui\u00a0Y, Sheng\u00a0L, Wang\u00a0K, Hu\u00a0Q, Wei\u00a0Q. Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy. Oncol Rep. 2008;19:435\u201340.","journal-title":"Oncol Rep"},{"key":"1778_CR27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.oraloncology.2012.05.005","volume":"48","author":"TS Clauditz","year":"2012","unstructured":"Clauditz\u00a0TS, Gontarewicz\u00a0A, Lebok\u00a0P, et\u00a0al. Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. Oral Oncol. 2012;48:991\u20136.","journal-title":"Oral Oncol"},{"key":"1778_CR28","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.18632\/oncotarget.3411","volume":"6","author":"H Liu","year":"2015","unstructured":"Liu\u00a0H, Du\u00a0L, Wang\u00a0R, et\u00a0al. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy. Oncotarget. 2015;6:11477\u201391.","journal-title":"Oncotarget"},{"key":"1778_CR29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.2011.605","volume":"106","author":"T Ettl","year":"2012","unstructured":"Ettl\u00a0T, Baader\u00a0K, Stiegler\u00a0C, et\u00a0al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106:719\u201326.","journal-title":"Br J Cancer"},{"key":"1778_CR30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jop.12064","volume":"42","author":"TS Clauditz","year":"2013","unstructured":"Clauditz\u00a0TS, Gontarewicz\u00a0A, Bokemeyer\u00a0C, et\u00a0al. Abundant expression of mTOR kinase in salivary gland tumors\u2014potentials as therapy target? J\u00a0Oral Pathol Med. 2013;42:769\u201373.","journal-title":"J Oral Pathol Med"},{"key":"1778_CR31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.oraloncology.2012.02.021","volume":"48","author":"T Ettl","year":"2012","unstructured":"Ettl\u00a0T, Schwarz-Furlan\u00a0S, Haubner\u00a0F, et al. The PI3K\/AKT\/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 2012;48:822\u201330.","journal-title":"Oral Oncol"},{"key":"1778_CR32","doi-asserted-by":"crossref","first-page":"23139","DOI":"10.1074\/jbc.M710308200","volume":"283","author":"S Yamamoto","year":"2008","unstructured":"Yamamoto\u00a0S, Fukumoto\u00a0E, Yoshizaki\u00a0K, et al. Platelet-derived growth factor receptor regulates salivary gland morphogenesis via fibroblast growth factor expression. J\u00a0Biol Chem. 2008;283:23139\u201349.","journal-title":"J Biol Chem"},{"key":"1778_CR33","doi-asserted-by":"crossref","first-page":"25631","DOI":"10.18632\/oncotarget.4554","volume":"6","author":"S Kato","year":"2015","unstructured":"Kato\u00a0S, Elkin\u00a0SK, Schwaederle\u00a0M, et\u00a0al. Genomic landscape of salivary gland tumors. Oncotarget. 2015;6:25631\u201345.","journal-title":"Oncotarget"},{"key":"1778_CR34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","volume":"40","author":"E Boon","year":"2018","unstructured":"Boon\u00a0E, van Boxtel\u00a0W, Buter\u00a0J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35\u00a0patients in the Netherlands. Head Neck. 2018;40:605\u201313.","journal-title":"Head Neck"},{"key":"1778_CR35","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/15384047.2015.1030554","volume":"16","author":"D Bell","year":"2015","unstructured":"Bell\u00a0D, Ferrarotto\u00a0R, Fox\u00a0MD, et al. Analysis and significance of c\u2011MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 2015;16:834\u20138.","journal-title":"Cancer Biol Ther"},{"key":"1778_CR36","doi-asserted-by":"crossref","first-page":"614845","DOI":"10.1155\/2015\/614845","volume":"2015","author":"A Popovtzer","year":"2015","unstructured":"Popovtzer\u00a0A, Sarfaty\u00a0M, Limon\u00a0D, et al. Metastatic salivary gland tumors: a single-center study demonstrating the feasibility and potential clinical benefit of molecular-profiling-guided therapy. Biomed Res Int. 2015;2015:614845.","journal-title":"Biomed Res Int"},{"key":"1778_CR37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","volume":"43","author":"MR Pfeffer","year":"2007","unstructured":"Pfeffer\u00a0MR, Talmi\u00a0Y, Catane\u00a0R, Symon\u00a0Z, Yosepovitch\u00a0A, Levitt\u00a0M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43:33\u20136.","journal-title":"Oral Oncol"},{"key":"1778_CR38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","volume":"23","author":"SJ Hotte","year":"2005","unstructured":"Hotte\u00a0SJ, Winquist\u00a0EW, Lamont\u00a0E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c\u2011kit: a\u00a0Princess Margaret Hospital phase II consortium study. J\u00a0Clin Oncol. 2005;23:585\u201390.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1778_CR39","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/jco.2007.25.18_suppl.6086","volume":"25","author":"JM Guigay","year":"2007","unstructured":"Guigay JM, Bidault F, Temam S,\u00a0et al. Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: A phase II study. J Clin Oncol. 2007;25(18):6086.","journal-title":"J Clin Oncol."},{"key":"1778_CR40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/hed.20094","volume":"26","author":"JC Alcedo","year":"2004","unstructured":"Alcedo\u00a0JC, Fabrega\u00a0JM, Arosemena\u00a0JR, Urrutia\u00a0A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck. 2004;26:829\u201331.","journal-title":"Head Neck"},{"key":"1778_CR41","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","volume":"23","author":"NG Chau","year":"2012","unstructured":"Chau\u00a0NG, Hotte\u00a0SJ, Chen\u00a0EX, et\u00a0al. A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23:1562\u201370.","journal-title":"Ann Oncol"},{"key":"1778_CR42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","volume":"27","author":"SJ Wong","year":"2016","unstructured":"Wong\u00a0SJ, Karrison\u00a0T, Hayes\u00a0DN, et al. Phase II trial of dasatinib for recurrent or metastatic c\u2011KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27:318\u201323.","journal-title":"Ann Oncol"},{"key":"1778_CR43","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","volume":"27","author":"AL Ho","year":"2016","unstructured":"Ho\u00a0AL, Dunn\u00a0L, Sherman\u00a0EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27:1902\u20138.","journal-title":"Ann Oncol"},{"key":"1778_CR44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","volume":"45","author":"LD Locati","year":"2009","unstructured":"Locati\u00a0LD, Bossi\u00a0P, Perrone\u00a0F, et\u00a0al. Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 2009;45:574\u20138.","journal-title":"Oral Oncol"},{"key":"1778_CR45","doi-asserted-by":"crossref","first-page":"18224","DOI":"10.18632\/oncotarget.4015","volume":"6","author":"I Grunewald","year":"2015","unstructured":"Grunewald\u00a0I, Vollbrecht\u00a0C, Meinrath\u00a0J, Wardelmann\u00a0E, et\u00a0al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget. 2015;6:18224\u201337.","journal-title":"Oncotarget"},{"key":"1778_CR46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.path.2016.04.002","volume":"9","author":"RR Seethala","year":"2016","unstructured":"Seethala\u00a0RR, Griffith\u00a0CC. Molecular pathology: predictive, prognostic, and diagnostic markers in salivary gland tumors. Surg Pathol Clin. 2016;9:339\u201352.","journal-title":"Surg Pathol Clin"},{"key":"1778_CR47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13054-017-1836-5","volume":"21","author":"CW Seymour","year":"2017","unstructured":"Seymour\u00a0CW, Gomez\u00a0H, Chang\u00a0CH, et\u00a0al. Precision medicine for all? Challenges and opportunities for a\u00a0precision medicine approach to critical illness. Crit Care. 2017;21:257.","journal-title":"Crit Care"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-020-01778-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01778-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:32:27Z","timestamp":1611747147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-020-01778-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":47,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1778"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01778-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"5 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Taghizadeh, L.\u00a0M\u00fcllauer, R.M.\u00a0Mader, T.\u00a0F\u00fcreder, and G.W.\u00a0Prager declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}